Literature DB >> 3103443

Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin.

J C Barton, G A Herrera, J H Galla, L F Bertoli, J Work, W J Koopman.   

Abstract

A 39-year-old woman had mixed IgM/IgG cryoglobulinemia, but was later found to have a lymphoma that produced an IgM kappa paraprotein with rheumatoid factor activity. With intermittent chlorambucil and prednisone therapy, the lymphoma was controlled for five years and she had no evidence of cryoglobulinemia. Because of the presence of intractable pulmonary infection and hypogammaglobulinemia G, she was given an intravenous infusion of gamma globulin. Within 72 hours, renal failure and a sustained decrease in serum concentrations of IgM and IgG began concurrently. A kidney biopsy specimen obtained five days after the infusion showed hyaline "thrombi" in numerous glomerular capillaries and glomerular necrosis, consistent with acute, severe mixed cryoglobulinemic nephropathy. Immunostaining showed strong positivity for IgM, IgG, and light chains in glomerular capillary lumina and subendothelial sites; immunostaining with a monoclonal antiidiotypic antibody specific for the patient's paraprotein established the presence of the rheumatoid factor paraprotein in the deposits. These observations strongly suggest that complexes consisting of IgM kappa rheumatoid factor, IgG, and complement initiated the renal damage. Therefore, demonstrable serum rheumatoid factor activity in patients with B cell neoplasms should be considered a contraindication to the administration of intravenous gamma globulin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3103443     DOI: 10.1016/0002-9343(87)90110-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

Review 1.  Cryoglobulins in chronic hepatitis C virus infection.

Authors:  M Trendelenburg; J A Schifferli
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

Review 2.  Current concepts in the treatment of immune thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

3.  Cryoglobulins are not essential.

Authors:  M Trendelenburg; J A Schifferli
Journal:  Ann Rheum Dis       Date:  1998-01       Impact factor: 19.103

Review 4.  Side-effects of intravenous immune globulins.

Authors:  C Duhem; M A Dicato; F Ries
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

Review 5.  Intravenous immunoglobulin treatment in vasculitis and connective tissue disorders.

Authors:  Andreas Steinbrecher; Peter Berlit
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

6.  Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice.

Authors:  I Krause; M Blank; Y Shoenfeld
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

Review 7.  Adverse effects of intravenous immunoglobulin.

Authors:  S A Misbah; H M Chapel
Journal:  Drug Saf       Date:  1993-10       Impact factor: 5.606

8.  Immune globulin therapy and kidney disease: Overview and screening, monitoring, and management recommendations.

Authors:  Roger H Kobayashi; Michael T Rigas
Journal:  Am J Health Syst Pharm       Date:  2022-08-19       Impact factor: 2.980

Review 9.  Symptomatic cryoglobulinemia.

Authors:  A Dispenzieri
Journal:  Curr Treat Options Oncol       Date:  2000-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.